Biocon share price
NSE: BIOCONPharma & HealthcareBiotechnology
Biocon at a glance
Biocon (NSE: BIOCON) closed at ₹330.00 on 22 Oct 2026, down 1.05% on the day. With a market capitalisation of ₹53,780 Cr, it ranks 187th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 116.6× trailing earnings, against a return on equity of 1.1% in FY26. Over the past year the share price has fallen 5.9%. Its 52-week range is ₹328.35 (22 Oct 2026) to ₹447.15 (16 Jul 2026); the last close is 26.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4,292 Cr (+9.8% year on year) and net profit ₹137 Cr (+53.4%), on a consolidated basis. Promoters held 44.68% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹53,780 CrRank 187 on NSE
- P/E (trailing)
- 116.6×
- Price to book
- 1.72×FY26
- EPS (TTM)
- ₹3.40to Q1 FY27
- ROE
- 1.1%FY26
- ROCE
- 3.7%FY26
- Debt to equity
- 0.44FY26
- Net profit margin
- 2.2%FY26
- Book value / share
- ₹209.94FY26
- 52-week high
- ₹447.1516 Jul 2026
- 52-week low
- ₹328.3522 Oct 2026
- 1-year return
- −5.9%
- RSI (14-day)
- 20.2
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.05% | −6.2% | −16.5% | −24.8% | −5.9% |
Biocon quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,590 Cr | ₹3,773 Cr | ₹4,358 Cr | ₹3,910 Cr | ₹4,263 Cr | ₹4,123 Cr | ₹4,484 Cr | ₹4,292 Cr |
| Revenue YoY | +3.7% | +6.3% | +12.8% | +13.9% | +18.7% | +9.3% | +2.9% | +9.8% |
| Net profit | ₹27 Cr | ₹81 Cr | ₹459 Cr | ₹89 Cr | ₹133 Cr | −₹52 Cr | ₹199 Cr | ₹137 Cr |
| Net profit YoY | −86.2% | −89.6% | +103.6% | −89.6% | +390.0% | −163.9% | −56.8% | +53.4% |
| Net margin | 0.8% | 2.1% | 10.5% | 2.3% | 3.1% | −1.3% | 4.4% | 3.2% |
| EPS | −₹0.13 | ₹0.21 | ₹2.88 | ₹0.26 | ₹0.66 | ₹1.08 | ₹0.79 | ₹0.87 |
Biocon financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹7,106 Cr | ₹8,184 Cr | ₹11,174 Cr | ₹14,756 Cr | ₹15,262 Cr | — |
| Operating profit | ₹1,134 Cr | ₹1,301 Cr | ₹1,356 Cr | ₹1,621 Cr | ₹1,790 Cr | — |
| Net profit | ₹916 Cr | ₹979 Cr | ₹810 Cr | ₹1,382 Cr | ₹1,429 Cr | — |
| EPS (₹) | ₹6.00 | ₹5.00 | ₹4.00 | ₹9.00 | ₹8.00 | — |
| Cash from operations | ₹1,160 Cr | ₹1,177 Cr | ₹1,853 Cr | ₹2,954 Cr | ₹4,061 Cr | — |
| Total debt | ₹2,962 Cr | ₹3,999 Cr | ₹15,291 Cr | ₹12,932 Cr | ₹12,405 Cr | ₹10,746 Cr |
| Shareholders' equity | ₹7,531 Cr | ₹8,433 Cr | ₹17,867 Cr | ₹19,784 Cr | ₹21,644 Cr | ₹34,032 Cr |
Biocon shareholding pattern
| Holder | 31 Dec 2025 | 5 Jan 2026 | 14 Jan 2026 | 31 Mar 2026 | 29 Jun 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.45% | 48.27% | 44.91% | 44.91% | 44.68% | 44.68% |
| Foreign institutions | 7.39% | 6.56% | 7.14% | 7.52% | 8.16% | 8.14% |
| Domestic institutions | 21.71% | 19.65% | 24.16% | 24.07% | 23.37% | 23.38% |
| Non-institutions | 16.33% | 25.42% | 23.69% | 23.41% | 23.74% | 23.75% |
Biocon vs peers
The listed Pharma & Healthcare companies nearest to Biocon by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALKEMAlkem Laboratories | ₹4,970.00 | −0.62% | −9.6% | ₹59,424 Cr | 25.8 | 16.6% |
| ASTERDMAster DM Health | ₹655.00 | +0.74% | −4.4% | ₹57,095 Cr | 102.3 | 8.5% |
| FORTISFortis Healthcare | ₹724.00 | −0.14% | −33.1% | ₹54,659 Cr | 52.6 | 10.5% |
| ABBOTINDIAAbbott India | ₹25,340.00 | −1.97% | −15.7% | ₹53,846 Cr | 34.7 | 33.4% |
| BIOCONBiocon | ₹330.00 | −1.05% | −5.9% | ₹53,780 Cr | 116.6 | 1.1% |
| IPCALABIPCA Laboratories | ₹1,899.80 | −1.10% | +45.9% | ₹48,199 Cr | 42.3 | 14.2% |
| GLANDGland Pharma | ₹2,850.00 | −2.73% | +48.8% | ₹47,014 Cr | 45.7 | 9.9% |
Ask anything about Biocon
Pivot answers on the live chart with evidence you can check, and tests strategies against BIOCON's own history. Try: “Why has BIOCON moved over the last three months?” · “Backtest a 50-day moving-average crossover on BIOCON over five years” · “Compare BIOCON with ALKEM on margins and valuation”
Frequently asked questions about Biocon
What is the share price of Biocon today?
Biocon (NSE: BIOCON) last closed at ₹330.00 on 22 Oct 2026. Its 52-week high is ₹447.15 and its 52-week low is ₹328.35.
What is the market cap of Biocon?
Biocon's market capitalisation is ₹53,780 Cr (₹53,780 Cr) at the 22 Oct 2026 close, ranking 187th among the NSE companies Pivot tracks.
What is the P/E ratio of Biocon?
Biocon trades at a trailing P/E of 116.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 45.7.
What is the ROE and ROCE of Biocon?
Return on equity was 1.1% in FY26 and return on capital employed was 3.7% in FY26 (consolidated figures).
Is Biocon a debt-free company?
No. Biocon's debt-to-equity ratio was 0.44 in FY26, with total debt of ₹10,746 Cr.
What were Biocon's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Biocon reported revenue of ₹4,292 Cr, +9.8% year on year, and net profit of ₹137 Cr, +53.4% year on year.
How has Biocon stock performed over the last year?
Biocon's share price has fallen 5.9% over the past year, −24.8% over three months and −16.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Biocon?
As of 30 Jun 2026: promoters 44.68%, foreign institutions 8.14%, domestic institutions 23.38%, non-institutions 23.75%.
Who are Biocon's competitors?
The listed Pharma & Healthcare companies closest to Biocon by market cap are Alkem Laboratories, Aster DM Health, Fortis Healthcare, Abbott India, IPCA Laboratories and Gland Pharma.
Is Biocon a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Biocon's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIOCON against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text